SL
PVLA

Siren LLC’s Palvella Therapeutics PVLA Stock Holding History

Siren LLC’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.1M Buy
257,485
+182,485
+243% +$19M 0.89% 31
2025
Q4 		$7.85M Buy
+75,000
New +$6.4M 0.23% 58

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Siren LLC's PVLA Position: Q1 2026 in Review

Siren LLC increased its Palvella Therapeutics (PVLA) stake by 243% in Q1 2026, buying an estimated $19M and bringing the position to 257,485 shares worth $32.1M. The position accounts for 0.89% of the portfolio, ranked #31.

Siren LLC first reported a position in PVLA in Q4 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Siren LLC held 257,485 shares of Palvella Therapeutics worth $32.1M as of Q1 2026.
  • Siren LLC bought 182,485 Palvella Therapeutics shares in Q1 2026, an estimated $19M.
  • Palvella Therapeutics made up 0.89% of Siren LLC's portfolio in Q1 2026, its #31 holding.
  • Siren LLC first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.